.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,214,848

« Back to Dashboard

Details for Patent: 6,214,848

Title: Pharmaceutical composition
Abstract:Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
Inventor(s): Ikeda; Hitoshi (Higashiosaka, JP), Sohda; Takashi (Takatsuki, JP), Odaka; Hiroyuki (Kobe, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Filing Date:Apr 30, 1999
Application Number:09/302,508
Claims:1. A pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with a LDL catabolism enhancer.

2. The pharmaceutical composition according to claim 1, wherein the insulin sensitivity enhancer is a compound represented by the formula: ##STR8##

wherein R represents an optionally substituted hydrocarbon or heterocyclic group; Y represents a group represented by --CO--, --CH(OH)-- or --NR.sup.3 -- wherein R.sup.3 represents an optionally substituted alkyl group; m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a bond or a C.sub.1-7 divalent aliphatic hydrocarbon group; Q represents oxygen atom or sulfur atom; R.sup.1 represents hydrogen atom or an alkyl group; ring E may optionally have further 1 to 4 substituents, and the substituents may optionally be combined with R.sup.1 to form a ring; L and M respectively represent hydrogen atom, or L and M may optionally be combined with each other to form a bond; or a pharmacologically acceptable salt thereof.

3. The pharmaceutical composition according to claim 2, wherein R is an optionally substituted heterocyclic group.

4. The pharmaceutical composition according to claim 2, wherein m is 0.

5. The pharmaceutical composition according to claim 2, wherein X is CH.

6. The pharmaceutical composition according to claim 2, wherein R.sup.1 is hydrogen atom.

7. The pharmaceutical composition according to claim 2, wherein the partial formula: ##STR9##

wherein R.sup.2 represents hydrogen atom, an alkyl group, an optionally substituted hydroxyl group, a halogen atom, an optionally substituted acyl group, nitro group or an optionally substituted amino group.

8. The pharmaceutical composition according to claim 2, wherein L and M are hydrogen atom.

9. The pharmaceutical composition according to claim 2, wherein R is pyridyl, oxazolyl or thiazolyl group optionally having 1 to 3 substituents selected from C.sub.1-3 alkyl, furyl, thienyl, phenyl and naphthyl; m is 0; n is 0 or 1; X is CH; A is a bond or --(CH.sub.2).sub.2 --; R.sup.1 is hydrogen atom; the partial formula: ##STR10##

and R.sup.2 is hydrogen atom or C.sub.1-4 alkoxy group; and L and M are both hydrogen atom.

10. The pharmaceutical composition according to claim 2, wherein the compound represented by the formula (I) is pioglitazone.

11. The pharmaceutical composition according to claim 1, wherein the insulin sensitivity enhancer is pioglitazone or its hydrochloride.

12. The pharmaceutical composition according to claim 1, wherein the insulin sensitivity enhancer is troglitazone.

13. The pharmaceutical composition according to claim 1, wherein the insulin sensitivity enhancer is 5-[[4-[2-(methyl-2-pyridylamino)ethoxy]phenyl]-methyl]-2,4-thiazolinedione or its pharmacologically acceptable salt.

14. The pharmaceutical composition according to claim 1, which is for prophylaxis or treatment of diabetes.

15. The pharmaceutical composition according to claim 1, which is for prophylaxis or treatment of diabetic complications.

16. A method for treating diabetes in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of an insulin sensitivity enhancer in combination with an LDL catabolism enhancer.

17. The method according to claim 16, wherein the insulin sensitivity enhancer is pioglitazone or its hydrochloride.

18. The method according to claim 16, wherein the insulin sensitivity enhancer is troglitazone.

19. The method according to claim 16, wherein the insulin sensitivity enhancer is 5-[[4-[2-(methyl-2-pyridylamino)ethoxy]phenyl]-methyl]-2,4-thiazolinedione or its pharmacologically acceptable salt.

20. The method according to claim 16, wherein the insulin sensitivity enhancer and LDL catabolism enhancer are mixed together to form an admixture and the admixture is administered to the mammal.

21. The method according to claim 16, wherein the insulin sensitivity enhancer and LDL catabolism enhancer are not mixed together but are administered independently to the mammal.

22. A method treating diabetic complications in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of an insulin sensitivity enhancer in combination with a LDL catabolism enhancer.

23. The method according to claim 22, wherein the insulin sensitivity enhancer is pioglitazone or its hydrochloride.

24. The method according to claim 22, wherein the insulin sensitivity enhancer is troglitazone.

25. The method according to claim 22, wherein the insulin sensitivity enhancer is 5-[[4-[2-(methyl-2-pyridylamino)ethoxy]phenyl]-methyl]-2,4-thiazolinedione or its pharmacologically acceptable salt.

26. The method according to claim 22, wherein the insulin sensitivity enhancer and LDL catabolism enhancer are mixed together to form an admixture and the admixture is administered to the mammal.

27. The method according to claim 22, wherein the insulin sensitivity enhancer and LDL catabolism enhancer are not mixed together but are administered independently to the mammal.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc